Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Prostatic Neoplasms 23Breast Neoplasms 16Neoplasms by Site 2Neoplasms 2Neoplasm Metastasis 2Breast Diseases 2Stage II Prostate Adenocarcinoma 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Salivary Gland Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Endometrial Neoplasms 1Dementia 1Cognitive Dysfunction 1Anatomic Stage III Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

exemestane 1Leuprolide 1Letrozole 1Holistic Health 1Goserelin 1Gonadotropin-Releasing Hormone 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sexual Dysfunctions, Psychological × Gonadotropin-Releasing Hormone × 1 year × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡